New Funds to Boost British Efforts to Develop Chlamydia Vaccine
By LabMedica International staff writers Posted on 16 Aug 2015 |
An infusion of new funding is expected to boost efforts by researchers in the United Kingdom to develop a vaccine to prevent Chlamydia infection.
Chlamydiae are small gram-negative obligate intracellular microorganisms that preferentially infect squamocolumnar epithelial cells. Chlamydia trachomatis infection, with nearly 200,000 new cases per year in the United Kingdom, is the most commonly reported bacterial sexually transmitted disease in the United States and a leading cause of infertility in women.
In a major effort to control the spread of chlamydial infection, the United Kingdom's Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; London, United Kingdom) has committed GBP 377,000 to aid in the development of a vaccine. The project will be conducted by Prokarium Ltd. (London, United Kingdom), a biotechnology company that develops transformational oral vaccines. Prokarium will add an additional 121,000 GBP to the research program.
The development effort will be shared by Prokarium and its collaborator, Dr. Robin Shattock, professor of mucosal infection and immunity at Imperial College London (United Kingdom). The plan is to complete the preclinical development of the Chlamydia vaccine in time for clinical trials in 2017.
Dr. Steve Chambers, CEO of SynbiCITE, said, "The new Prokarium vaccine was selected for funding because the need for a Chlamydia vaccine is significant and the potential for this approach both for Chlamydia and as a model for treating other infections in the medium-term is very encouraging.”
Dr. Steve Chatfield, chairman of Prokarium, said, “This SynbiCITE funding allows us to test a vaccine against the one of the world’s most serious sexually transmitted infections. Prokarium is now well set up to work with the best of the best in the vaccine arena.”
Related Links:
SynbiCITE
Prokarium Ltd.
Imperial College London
Chlamydiae are small gram-negative obligate intracellular microorganisms that preferentially infect squamocolumnar epithelial cells. Chlamydia trachomatis infection, with nearly 200,000 new cases per year in the United Kingdom, is the most commonly reported bacterial sexually transmitted disease in the United States and a leading cause of infertility in women.
In a major effort to control the spread of chlamydial infection, the United Kingdom's Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; London, United Kingdom) has committed GBP 377,000 to aid in the development of a vaccine. The project will be conducted by Prokarium Ltd. (London, United Kingdom), a biotechnology company that develops transformational oral vaccines. Prokarium will add an additional 121,000 GBP to the research program.
The development effort will be shared by Prokarium and its collaborator, Dr. Robin Shattock, professor of mucosal infection and immunity at Imperial College London (United Kingdom). The plan is to complete the preclinical development of the Chlamydia vaccine in time for clinical trials in 2017.
Dr. Steve Chambers, CEO of SynbiCITE, said, "The new Prokarium vaccine was selected for funding because the need for a Chlamydia vaccine is significant and the potential for this approach both for Chlamydia and as a model for treating other infections in the medium-term is very encouraging.”
Dr. Steve Chatfield, chairman of Prokarium, said, “This SynbiCITE funding allows us to test a vaccine against the one of the world’s most serious sexually transmitted infections. Prokarium is now well set up to work with the best of the best in the vaccine arena.”
Related Links:
SynbiCITE
Prokarium Ltd.
Imperial College London
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples